Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Don't be tempted to take profit on Treatt following recent share price spike

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Treatt (TET) 917.52p
Gain to date: 51%
Original entry point: Buy at 607p, 29 October 2020
Shares in extracts-to-ingredients supplier Treatt (TET) have risen by 51% since we said to buy last October. The company says annual profits are expected to ‘materially’ exceed the £15.1 million market consensus and prompted analysts to raise their earnings expectations.
While some investors will be put off by the shares now trading on 37.3 times upgraded earnings forecasts, there is good reason to keep them in your portfolio.
A new UK plant is scheduled to become operational this summer, which will deliver ‘a step change in terms of capacity, capabilities and potential margins,’ says broker Peel Hunt.
‘We see Treatt as on a virtuous circle, where stronger growth is both delivering higher profits and funds to invest in additional capability and capacity.’
Treatt is performing particularly well in its citrus, health and wellness, fruit and vegetables and tea categories and has seen some material new business wins, including in the rapidly growing global alcoholic seltzer category.
As a supplier of natural extracts including its sugar reduction solutions, Treatt is well positioned to profit from the war on obesity post-Covid.
SHARES SAYS: We sense there will be some profit taking by investors in the coming days following the recent spike in the share price, but we see merit in sticking with Treatt longer term as it becomes a stronger business.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.